Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

British Journal of Cancer

Volumn 81, Issue 2, 1999, Pages 330-335

  Van Tellingen, O ^a   Huizing, M T ^b   Nannan Panday, V R ^b   Schellens, J H M ^c   Nooijen, W J ^a   Beijnen, J H ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c NONE

Author keywords

Free fraction; In vitro dialysis; Pharmacokinetic pharmacodynamic relationship; Plasma ultrafiltrate

Indexed keywords

CARBOPLATIN; CREMOPHOR; EXCIPIENT; MITOMYCIN C; NITROSOUREA; PACLITAXEL;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MICELLE; MOLECULAR WEIGHT; OVARY CANCER; PHARMACOKINETICS; PRIORITY JOURNAL;

AREA UNDER CURVE; DIALYSIS; GLYCEROL; HUMANS; PACLITAXEL; SURFACE-ACTIVE AGENTS; VEHICLES;

EID: 0032833650     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690696     Document Type: Article

References (19)

1. Gengo FM, Schentag JJ and Jusko WJ (1984) Pharmacokinetics of capacity-limited distribution of methicillin in rabbits. J Pharm Sci 73: 867-873
2. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G and Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13: 180-190
3. Huizing MT, Keung AC, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM and Beijnen JH (1993) Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2127-2135
4. Huizing MT, Sewberath Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM and Beijnen JH (1995a) Taxanes; a new class of antitumor agents. Cancer Invest 13: 381-404
5. Huizing MT, Sparreboom A, Rosing H, Van Tellingen O, Pinedo HM and Beijnen JH (1995b) Quantification of paclitaxel metabolics in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 674: 261-268
6. Huizing MT, Giaccone G, Van Warmerdam LJC, Rosing H, Bakker PJM, Vermorken JB, Postmus PE, Van Zandwijk N, Koolen MGJ, ten Bokkel Huinink WW, Van der Vijgh WJF, Bierhorst FJ, Lai A, Dalesio O, Pinedo HM, Veenhof CHN and Beijnen JH (1997) Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. J Clin Oncol 15: 317-329
7. Jonkman-de Vries JD, Flora KP, Bult A and Beijnen JH (1996) Pharmaceutical development of (investigational) anticancer agents - a review. Drug Dev Indust Pharm 22: 475-494
8. Kearns CM, Gianni L and Egorin MJ (1995) Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22: 16-23
9. Meerum Terwogt JM, Beijnen JH, ten Bokkel Huinink WW, Rosing H and Schellens JHM (1998) Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 352: 285
10. Rischin D, Webster LK, Millward MJ, Linahan BM, Toner GC Woollett AM, Morton CG and Bishop JF (1996) Cremophor pharmacokinetics in patients receiving 3-, 6, and 24-hour infusions of paclitaxel. J Natl Cancer Inst 88: 1297-1301
11. Rowinsky EK and Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332: 1004-1014
12. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ and Relling MV (1994) Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12: 532-538
13. Sparreboom A, Van Tellingen O, Huizing MT, Nooijen WJ and Beijnen JH (1996a) Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. J Chromatorg 681: 355-361
14. Sparreboom A, Van Tellingen O, Nooijen WI and Buijnen JH (1996b) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL, Cancer Res 56: 2112-2115
15. Sparreboom A, Van Tellingen O, Nooijen WJ and Beijnen JH (1996c) Tissue distribution, metabolism and exeretion of paclitaxel in mice. Anticancer Drugs 7: 78-86
16. Sparreboom A, Loos WJ, Verweij J, Devos AI, Van der Burg MEL, Stoter G and Nooter K (1998a) Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. Anal Biochem 255: 171-175
17. Sparreboom A, Verweij J, Van der Burg MEL, Loos WJ, Brouwer E, Vigano L, Lacatelli A, de Vos AI, Nooter K, Stoler G and Gianni I. (1998b) Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 4: 1937-1942
18. Van Tellingen O, Sparreboom A, Huizing MT, Nooijen WJ and Beijnen JH (1996) The analysis and preliminary pharmacokinetics of Cremophor EL in human plasma. Ann Oncol 7: 92
19. Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J and Woodcock D (1993) Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 85: 1685-1690